Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC): A case report

Janakiraman Subramanian, Giancarlo Pillot, Vamsidhar Narra, Ramaswamy Govindan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

A 65-year-old male with 40-pack year smoking history presented with exertional dyspnea and was subsequently diagnosed with bronchiolo-alveolar carcinoma (BAC). He did not respond to first line therapy with geftinib, but he achieved disease stabilization with gemcitabine and carboplatin for 4 months before developing symptomatic worsening requiring oxygen supplementation. He responded dramatically to bortezomib with rapid symptom improvement. The follow-up computerized tomography revealed partial response that was maintained for 11 months. Based on observations like this and those seen in phase I studies with bortezomib, this agent is being studied now in patients with bronchio-alevolar cancer.

Original languageEnglish
Pages (from-to)257-259
Number of pages3
JournalLung Cancer
Volume51
Issue number2
DOIs
StatePublished - Feb 2006

Keywords

  • Bortezomib
  • Bronchiolo-alveolar carcinoma
  • Non-small cell lung cancer

Fingerprint

Dive into the research topics of 'Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC): A case report'. Together they form a unique fingerprint.

Cite this